Identification of negative predictors of pain-free response to triptans

Analysis of the eletriptan database

H. C. Diener, David William Dodick, P. J. Goadsby, R. B. Lipton, M. Almas, B. Parsons

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials (n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors (n = 2010; 24% of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P < 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalCephalalgia
Volume28
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Tryptamines
Sumatriptan
Databases
Placebos
Headache
Hyperacusis
Photophobia
Migraine Disorders
Nausea
Multivariate Analysis
Regression Analysis
Pain
eletriptan
Pain-Free
Therapeutics

Keywords

  • Eletriptan
  • Migraine
  • Risk factors
  • Sumatriptan
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Identification of negative predictors of pain-free response to triptans : Analysis of the eletriptan database. / Diener, H. C.; Dodick, David William; Goadsby, P. J.; Lipton, R. B.; Almas, M.; Parsons, B.

In: Cephalalgia, Vol. 28, No. 1, 01.2008, p. 35-40.

Research output: Contribution to journalArticle

Diener, H. C. ; Dodick, David William ; Goadsby, P. J. ; Lipton, R. B. ; Almas, M. ; Parsons, B. / Identification of negative predictors of pain-free response to triptans : Analysis of the eletriptan database. In: Cephalalgia. 2008 ; Vol. 28, No. 1. pp. 35-40.
@article{7c947db4163f41be92a4a3f80297810a,
title = "Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database",
abstract = "Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials (n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors (n = 2010; 24{\%} of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P < 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans.",
keywords = "Eletriptan, Migraine, Risk factors, Sumatriptan, Triptans",
author = "Diener, {H. C.} and Dodick, {David William} and Goadsby, {P. J.} and Lipton, {R. B.} and M. Almas and B. Parsons",
year = "2008",
month = "1",
doi = "10.1111/j.1468-2982.2007.01457.x",
language = "English (US)",
volume = "28",
pages = "35--40",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Identification of negative predictors of pain-free response to triptans

T2 - Analysis of the eletriptan database

AU - Diener, H. C.

AU - Dodick, David William

AU - Goadsby, P. J.

AU - Lipton, R. B.

AU - Almas, M.

AU - Parsons, B.

PY - 2008/1

Y1 - 2008/1

N2 - Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials (n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors (n = 2010; 24% of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P < 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans.

AB - Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials (n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors (n = 2010; 24% of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P < 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans.

KW - Eletriptan

KW - Migraine

KW - Risk factors

KW - Sumatriptan

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=36749093479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749093479&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2007.01457.x

DO - 10.1111/j.1468-2982.2007.01457.x

M3 - Article

VL - 28

SP - 35

EP - 40

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 1

ER -